Interleukin‑8 promotes prostate cancer bone metastasis through upregulation of bone sialoprotein

Liu,Baohao; Xu,Meng; Guo,Zhongqing; Liu,Jiajie; Chu,Xu; Jiang,Huamao

doi:10.3892/ol.2019.10138

Interleukin‑8 promotes prostate cancer bone metastasis through upregulation of bone sialoprotein

Authors:
- Baohao Liu
- Meng Xu
- Zhongqing Guo
- Jiajie Liu
- Xu Chu
- Huamao Jiang
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121000, P.R. China
Published online on: March 12, 2019 https://doi.org/10.3892/ol.2019.10138
Pages: 4607-4613
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate whether interleukin‑8 (IL‑8) enhances the ability of prostate cancer bone metastasis by influencing the coding level of bone sialoprotein (BSP). Cultured prostate cancer cell lines LNCaP (androgen dependent) and DU145 (androgen independent) were divided into three groups: IL‑8 treatment group; IL‑8 receptor inhibitor (SB225002) treatment group; and control group. Western blotting and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) were used to detect BSP protein and mRNA expression levels. Matrigel and bone adhesion experiments were used to detect the invasiveness of cancer cells and bone adhesion changes. Compared with the control group, western blotting and RT‑qPCR results indicated that BSP protein and mRNA levels in LNCaP and DU145 were significantly upregulated following IL‑8 treatment. Matrigel experiments indicated that following IL‑8 treatment, the invasiveness of LNCaP and DU145 cells was significantly increased. The results of bone adhesion experiments indicated that following IL‑8 treatment, the number of DU145 cells adhered to the surface of the bone was increased, compared with the control group. Following treatment of both cell lines with SB225002, western blotting and RT‑qPCR results indicated that the expression levels of BSP protein and mRNA were significantly downregulated. Matrigel experiments indicated that following SB225002 treatment, the invasiveness of LNCaP and DU145 cells was significantly reduced. The number of DU145 cells adhered to the surface of the bone was reduced, compared with the untreated group. Therefore, IL‑8 may promote prostate cancer bone metastasis by enhancing BSP regulation.

View Figures

View References

1	Chen K, Wu K, Jiao X, Wang L, Ju X, Wang M, Di Sante G, Xu S, Wang Q, Li K, et al: The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a CXCL signaling module. Cancer Res. 75:1992–2004. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. Ca Cancer J Clin. 54:8–29. 2015.
3	Chaplet M, Waltregny D, Detry C, Fisher LW, Castronovo V and Bellahcène A: Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer. 118:850–856. 2006. View Article : Google Scholar : PubMed/NCBI
4	Sung V, Cattell DA, Bueno JM, Murray A, Zwiebel JA, Aaron AD and Thompson EW: Human breast cancer cell metastasis to long bone and soft organs of nude mice: A quantitative assay. Clin Exp Metastasis. 15:173–183. 1997. View Article : Google Scholar : PubMed/NCBI
5	Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat Rev Cancer. 8:212–226. 2008. View Article : Google Scholar : PubMed/NCBI
6	Anunobi CC, Koli K, Saxena G, Banjo AA and Ogbureke KU: Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms. Oncotarget. 7:48038–48049. 2016. View Article : Google Scholar : PubMed/NCBI
7	Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA and Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 6:2104–2119. 2000.PubMed/NCBI
8	Bellahcène A, Merville MP and Castronovo V: Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 54:2823–2826. 1994.PubMed/NCBI
9	Neveu B, Moreel X, Deschênes-Rompré MP, Bergeron A, LaRue H, Ayari C, Fradet Y and Fradet V: IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. Res Reports Urol. 2014:27–34. 2014.
10	Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY and Hayes RB: Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 66:4525–4530. 2016. View Article : Google Scholar
11	Goda AE, Koyama M, Sowa Y, Elokely KM, Yoshida T, Kim BY and Sakai T: Molecular mechanisms of the antitumor activity of SB225002: A novel microtubule inhibitor. Biochem Pharmacol. 85:1741–1752. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hamilton SL, Ferando B, Eapen AS, Yu JC and Joy AR: Cancer secretome may influence BSP and DSP expression in human salivary gland cells. J Histochem Cytochem. 65:139–151. 2017. View Article : Google Scholar : PubMed/NCBI
13	de Vasconcellos JF, Laranjeira AB, Leal PC, Bhasin MK, Zenatti PP, Nunes RJ, Yunes RA, Nowill AE, Libermann TA, Zerbini LF and Yunes JA: SB225002 induces cell death and cell cycle arrest in acute lymphoblastic leukemia cells through the activation of GLIPR1. PLoS One. 10:e01347832015. View Article : Google Scholar : PubMed/NCBI
14	Du M, Qiu Q, Gruslin A, Gordon J, He M, Chan CC, Li D and Tsang BK: SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro. PLoS One. 8:e545722013. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Xu M, Jaing H, Wang H, Liu J, Liu B and Guo Z: SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP-2. Oncol Rep. 40:726–736. 2018.PubMed/NCBI
17	Tu Q, Zhang J, Fix A, Brewer E, Li YP, Zhang ZY and Chen J: Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol. 218:135–145. 2009. View Article : Google Scholar : PubMed/NCBI
18	Luca M, Huang S, Gershenwald JE, Singh RK, Reich R and Bar-Eli M: Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 151:1105–1113. 1997.PubMed/NCBI
19	Pold M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PP, Põld A, Luo J, Krysan K, Dohadwala M, et al: Cyclooxygenase-2 dependent expression of angiogenic CXC chemokines, ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8, in human non-small cell lung cancer. Cancer Res. 64:1853–1860. 2004. View Article : Google Scholar : PubMed/NCBI
20	Mahboob S, Ahn SB, Cheruku HR, Cantor D, Rennel E, Fredriksson S, Edfeldt G, Breen EJ, Khan A, Mohamedali A, et al: A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers. Clin Proteomics. 12:102015. View Article : Google Scholar : PubMed/NCBI
21	Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F and Lazennec G: IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene. 22:256–265. 2003. View Article : Google Scholar : PubMed/NCBI
22	Jain A, Mcknight DA, Fisher LW, Humphreys EB, Mangold LA, Partin AW and Fedarko NS: Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res. 15:5199–5207. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhang JH, Tang J, Wang J, Ma W, Zheng W, Yoneda T and Chen J: Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol. 23:1043–1048. 2003.PubMed/NCBI
24	Gordon JA, Sodek J, Hunter GK and Goldberg HA: Bone sialoprotein stimulates focal adhesion-related signaling pathways: Role in migration and survival of breast and prostate cancer cells. J Cell Biochem. 107:1118–1128. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang J, Wang L, Xia B, Yang C, Lai H and Chen X: BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells. PLoS One. 8:e629362013. View Article : Google Scholar : PubMed/NCBI
26	Zhang JH, Wang J, Tang J, Barnett B, Dickson J, Hahsimoto N, Williams P, Ma W, Zheng W, Yoneda T, et al: Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. Anticancer Res. 24:1361–1368. 2004.PubMed/NCBI
27	Wei RJ, Li TY, Yang XC, Jia N, Yang XL and Song HB: Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases. Genet Mol Res. 15:2015.
28	Riminucci M, Corsi A, Peris K, Fisher LW, Chimenti S and Bianco P: Coexpression of bone sialoprotein (BSP) and the pivotal transcriptional regulator of osteogenesis, Cbfa1/Runx2, in malignant melanoma. Calcif Tissue Int. 73:281–289. 2003. View Article : Google Scholar : PubMed/NCBI
29	Bellahcène A, Bonjean K, Fohr B, Fedarko NS, Robey FA, Young MF, Fisher LW and Castronovo V: Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res. 86:885–891. 2000. View Article : Google Scholar : PubMed/NCBI
30	Righi L, Bollito E, Ceppi P, Mirabelli D, Tavaglione V, Chiusa L, Porpiglia F, Brunelli M, Martignoni G, Terrone C and Papotti M: Prognostic role of bone sialoprotein in clear cell renal carcinoma. Anticancer Res. 33:2679–2687. 2013.PubMed/NCBI